Page 23 - AN-2-2

Advanced Neurology A novel approach to mitigate muscle atrophy in GBS

14. Berciano J, (2021), Axonal degeneration in Guillain-Barré 26. Derde S, Hermans G, Derese I, et al., (2012), Muscle atrophy
syndrome: A reappraisal. J Neurol, 268: 3728–3743. and preferential loss of myosin in prolonged critically ill
patients. Crit Care Med, 40: 79–89.
https://doi.org/10.1007/s00415-020-10034-y
https://doi.org/10.1097/CCM.0b013e31822d7c18
15. Koike H, Fukami Y, Nishi R, et al., (2020), Ultrastructural
mechanisms of macrophage-induced demyelination in 27. Atherton PJ, Smith K, (2012), Muscle protein synthesis in
Guillain-Barré syndrome. J Neurol Neurosurg Psychiatry, response to nutrition and exercise. J Physiol, 590: 1049–1057.
91: 650–659.
https://doi.org/10.1113/JPHYSIOL.2011.225003
https://doi.org/10.1136/JNNP-2019-322479
28. Van Den Berghe G, (2016), On the neuroendocrinopathy of
16. Koike H, Katsuno M, (2021), Macrophages and critical illness: Perspectives for feeding and novel treatments.
autoantibodies in demyelinating diseases. Cells, 10: 844. Am J Respir Crit Care Med, 194: 1337–1348.
https://doi.org//10.3390/cells10040844 https://doi.org/10.1164/rccm.201607-1516CI
17. Albert LJ, Inman RD, (1999), Molecular mimicry and 29. Mitch WE, Goldberg AL, (1996), Mechanisms of muscle
autoimmunity. N Engl J Med, 341: 2068–2074. wasting-the role of the ubiquitin-proteasome pathway.
N Engl J Med, 335: 1897–1905.
https://doi.org//10.1056/NEJM199912303412707
https://doi.org/10.1056/NEJM199612193352507
18. Koike H, Chiba A, Katsuno M, (2021), Emerging infection,
vaccination, and Guillain-Barré syndrome: A review. Neurol 30. Brink M, Anwar A, Delafontaine P, (2002), Neurohormonal
Ther, 10: 523–537. factors in the development of catabolic/anabolic imbalance
and cachexia. Int J Cardiol, 85: 111–121; discussion 121–124.
https://doi.org/10.1007/s40120-021-00261-4
31. Cheung K, Rathbone A, Melanson M, et al., (2021),
19. Laman JD, Huizinga R, Boons GJ, et al., (2022), Guillain- Pathophysiology and management of critical illness
Barré syndrome: Expanding the concept of molecular polyneuropathy and myopathy. J Appl Physiol (1985),
mimicry. Trends Immunol, 43: 296–308.
130: 1479–1489.
https://doi.org/10.1016/j.it.2022.02.003
https://doi.org/10.1152/japplphysiol.00019.2021
20. Huizinga R, van den Berg B, van Rijs W, et al., (2015), 32. Powers SK, Kavazis AN, DeRuisseau KC, (2005),
Innate immunity to Campylobacter jejuni in Guillain-Barré Mechanisms of disuse muscle atrophy: Role of oxidative
syndrome. Ann Neurol, 78: 343–354.
stress. Am J Physiol Regul Integr Comp Physiol, 288: R337–
https://doi.org/10.1002/ANA.24442 R344.
21. Lleixà C, Martín-Aguilar L, Pascual-Goñi E, et al., (2021), https://doi.org/10.1152/ajpregu.00469.2004
Autoantibody screening in Guillain-Barré syndrome.
J Neuroinflammation, 18: 251. 33. Grosu HB, Lee YI, Lee J, et al., (2012), Diaphragm muscle
thinning in patients who are mechanically ventilated. Chest,
https://doi.org/10.1186/s12974-021-02301-0 142: 1455–1460.
22. Van Den Berg B, Walgaard C, Drenthen J, et al., (2014), https://doi.org/10.1378/CHEST.11-1638
Guillain-Barré syndrome: Pathogenesis, diagnosis,
treatment and prognosis. Nat Publ Gr, 10: 469–482. 34. Zambon M, Beccaria P, Matsuno J, et al., (2016), Mechanical
ventilation and diaphragmatic atrophy in critically ill
https://doi.org/10.1038/nrneurol.2014.121 patients: An ultrasound study. Crit Care Med, 44: 1347–1352.
23. Kusunoki S, Kaida KI, Ueda M, (2008), Antibodies against https://doi.org/10.1097/CCM.0000000000001657
gangliosides and ganglioside complexes in Guillain-Barré
syndrome: New aspects of research. Biochim Biophys Acta, 35. Bodine SC, Latres E, Baumhueter S, et al., (2001),
Identification of ubiquitin ligases required for skeletal
1780: 441–444.
muscle atrophy. Science, 294: 1704–1708.
https://doi.org/10.1016/j.bbagen.2007.10.001
https://doi.org/10.1126/SCIENCE.1065874
24. Kuwabara S, Yuki N, (2013), Axonal Guillain-Barré 36. Kondo H, Miura M, Itokawa Y, (1993), Antioxidant enzyme
syndrome: Concepts and controversies. Lancet Neurol, systems in skeletal muscle atrophied by immobilization.
12: 1180–1188.
Pflügers Arch, 422: 404–406.
https://doi.org/10.1016/S1474-4422(13)70215-1
https://doi.org/10.1007/BF00374299
25. Hermans G, De Jonghe B, Bruyninckx F, et al., (2008), 37. O’Loghlen A, Pérez-Morg/ado MI, Salinas M, et al., (2006),
Clinical review: Critical illness polyneuropathy and N-acetyl-cysteine abolishes hydrogen peroxide-induced
myopathy. Crit Care, 12: 238.
modification of eukaryotic initiation factor 4F activity via
https://doi.org/10.1186/cc7100 distinct signalling pathways. Cell Signal, 18: 21–31.

Volume 2 Issue 2 (2023) 9 https://doi.org/10.36922/an.280